Market Overview

Stemline Therapeutics (NASDAQ: STML)

4.42 -0.42 (-8.68%)

Analyst Ratings

DateResearch FirmActionCurrentPT
3/27/20Cantor FitzgeraldReiteratesOverweight10.0
3/26/20JP MorganMaintainsOverweight8.0
3/23/20Aegis CapitalMaintainsBuy
3/17/20WedbushMaintainsOutperform11.0
3/17/20HC Wainwright & Co.MaintainsBuy18.0
1/21/20H.C. WainwrightReiteratesBuy20.0
1/16/20WedbushMaintainsOutperform14.0
12/24/19Cantor FitzgeraldInitiates Coverage OnOverweight18.0
11/11/19WedbushMaintainsOutperform17.0
5/13/19WedbushDowngradesNeutral

Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!

Sign up to receive Benzinga's Daily Ratings Newsletter